03 May 2012 | 10:22 am |
International law firm Pinsent Masons has advised Retroscreen, an antiviral clinical trials specialist, on its admission to the AIM market of the London Stock Exchange, raising £15m and with a market capitalisation of £32.8m.
Retroscreen is a virology healthcare business which provides clinical and pre-clinical analytical services for flu and cold antiviral products to global pharmaceutical and biotechnology organisations. As the business develops, it intends to expand into adjacent clinical areas, such as asthma.
Kym Denny, CEO of Retroscreen, said: "I am delighted that Retroscreen has today joined AIM and I would like to welcome all our new shareholders to the Company. It is a very exciting day for Retroscreen, and one which we believe will be transformational for the development of the business.”
The Pinsent Masons team advising on the deal was led by Corporate Partner Russell Booker, assisted by Corporate Senior Associate Iain Butler, Corporate Solicitor James Paton-Philip, Legal Director Louise Fullwood (Commercial), Employment Partner Michael Ryley and Tax Senior Associate Conor Brindley.
Commenting on the deal, Russell said: "We are delighted to have assisted Retroscreen with the AIM listing, which will enable the business to expand its clinical and pre-clinical offering in the UK."
Multinational law firm Pinsent Masons has launched a new working-from home audit tool to help financial services organisations understand the hidden litigation and regulatory risks associated with staff increasingly working from home on a more permanent basis.
Multinational law firm Pinsent Masons is advising Seraphine Group plc, an international digitally-led maternity and nursing wear, on its IPO and premium listing on the main market of the London Stock Exchange.
Multinational law firm Pinsent Masons has today signed a memorandum of understanding (MOU) with Nepal International ADR Center (NIAC), commencing an important collaborative relationship seeking to enhance NIAC’s international arbitration capabilities.
For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on